82 results about "Neuroregulation" patented technology

Disclosed are methods and systems for treatment planning for deep brain or superficial neuromodulation using ultrasound and other treatment modalities impacting one or multiple points in a neural circuit to produce acute effects or Long-Term Potentiation (LTP) or Long-Term Depression (LTD) to treat indications such as neurologic and psychiatric conditions. Ultrasound transducers or other energy sources are positioned and the anticipated effects on up-regulation and/or down-regulation of their direction of energy emission, intensity, frequency, firing/timing pattern, and phase/intensity relationships mapped onto the recommended treatment-planning targets. The maps of treatment-planning targets onto which the mapping occurs can be atlas (e.g., Tailarach Atlas) based or image (e.g., fMRI or PET) based. Atlas and imaged-based maps may be representative and applied directly or scaled for the patient or may be specific to the patient.

The present invention provides a single surgical method, procedure and/or system that creates open visual and physical access to an identified spinal treatment site that initially comprises spinal levels to be treated, wherein the spinal levels comprise at least one dorsal root ganglion. A spinal treatment procedure is performed generally in combination with implantation of a neuromodulation system that may comprise placement of electrical lead(s) on the at least one dorsal root ganglion, wherein each lead is in operative connection with a pulse generator that may also be implanted during the surgical method. Electrical stimulation may be generated with the pulse generator through the electrical leads to the at least one dorsal root ganglion during and/or after the closure of the identified spinal treatment site.

The invention expands indications of a neuregulin in cardiovascular diseases, including sinus tachycardia and chronic atrial fibrillation. When the neuregulin is given to a mammal, the electrocardiogram PR interval thereof is found to be prolonged, and the heart rate is slowed down. The effect of slowing down the heart rate of the neuregulin can be used for anti-arrhythmias, and the chronic effect on the vagus nerve activity thereof can be used for treating sinus tachycardia and chronic atrial fibrillation.

It is intended to provide a safe composition for preventing or treating obesity or related complications which has an autonomic nervous control effect, in particular, an effect of enhancing sympathetic nervous activity and an effect of promoting energy metabolism. Thus, a medicinal composition, a food or a drink containing 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one and having an autonomic nervous control effect and an effect of promoting energy metabolism is provided.

The present disclosure provides a method and system for treating affective disorders such as depression and/or anxiety and/or related disorders through neuromodulatory intervention that includes brain targets within the orbitofrontal cortex (OFC). This method includes the application of electrical stimulation through an electrical signal generator device where the distal end of the device comprises at least one stimulating electrode in contact with the OFC. The treatment system includes patient selection, implantation of at least one stimulating electrode in contact with the OFC, acute or chronic electrical stimulation of the OFC, and evaluation of the effects of stimulation on clinical symptoms and status.

The invention discloses application of galanthamine in prevention and treatment for soybean meal-induced enteritis of fishes. According to a neuroregulation theory of intestinal mucosal immunity, in combination with two methods of disease modeling and biological information analysis, it is inferred that the galanthamine is a potential medicine for preventing and treating the soybean meal-induced enteritis; it is proved by an experiment that the galanthamine can activate expression of anti-inflammatory cytokines in intestinal tracts of bred fishes through addition into feed or intramuscular injection in backs, inhibit intestinal inflammations, maintain tight junctions of intestinal epithelium barriers, and inhibit intestinal epithelium apoptosis, therefore the enteritis caused by a soybeanmeal feed is relieved, recovery of growth of the fishes can be achieved, and therefore the galanthamine can be taken as a novel feed additive with an anti-inflammatory effect or an injection with an anti-inflammatory effect for injection operation.

The invention discloses a natural galenical for treating gynecologic diseases, which comprises the following raw materials in parts by weight: 1-3 parts of motherwort, 1-5 parts of dandelion, 1-2 parts of plantain, 2-4 parts of willow and 1-3 parts of white tea. The preparation method of the natural galenical comprises the following steps: extracting the motherwort, the dandelion, the plantain, the willow and the white tea and mixing according to a certain proportion so as to prepare the natural galenical. All the medicaments of the invention are completely extracted by adopting purely natural plants, can effectively act on the organism nerve of a person, regulate the endocrine system in the organism, can secrete mucus to protect the mucous membrane of the cavity tract, enhance the immunity of the organism, resist bacteria and diminish inflammation, thereby acting as a rehabilitation function. By clinical experiments, the total treatment effect of the invention is obviously enhanced in comparison with the traditional medicine, and pelvic inflammation can be radically cured.

The invention discloses a bee venom rheumatism ointment and a preparation method and use thereof, and relates to the field of Chinese herbal medicine. The ointment is made by taking bee venom as a monarch drug, selecting 15-20 parts of rhizoma chuanxiong, 15-20 parts of radix saposhnikoviae, 10-15 parts of myrrh, 15-20 parts of radix angelicae, 10-15 parts of radix scrophulariae, 10-15 parts of radix angelicae pubescentis, 10-15 parts of flos carthami, 2 parts of menthol, 3 parts of camphor and 1 part of borneol to serve as raw materials to be decocted, and adding 0.2 gram of dry bee venom into every 100 grams of the ointment. The ointment can be prepared through decoction with water or decoction with oil, the added dry bee venom and the components of the ointment can assist in the absorption of the bee venom, and the anaphylactic reaction of the human body to the bee venom is eliminated; the functions of inflammatory resistance and neuroregulation of the bee venom can enhance the effects of relieving pain and inflammation of the ointment; the ointment has the effects of antiphlogosis, relieving pain, promoting blood circulation to remove blood stasis, and dispelling wind and eliminating dampness.

Featured are intravaginal devices and electrical stimulation devices, systems, thereof, and methods of using the devices and systems thereof to observe pelvic floor movements in order to diagnose, treat, or prevent urinary and fecal incontinence disorders (e.g., urge incontinence) and their accompanying symptoms or to diagnose and/or improve the efficacy of neuromodulation therapy.

Methods of use, formulations, and devices for delivering therapeutic drugs locally to the region of the spleen are described herein. A method for treating sepsis and other inflammatory disease conditions can include inserting a drug delivery system inside the body, advancing the device to the spleen through the splenic artery, splenic vein or other blood vessel adjacent to the splenic nerves, or within a ligament associated with the spleen, such as the splenorenal or gastrosplenic ligaments.

Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include analyzing a renal neuromodulation target site of a patient to obtain patient-specific data related to the renal neuromodulation target site, and based on the patient specific data, delivering neuromodulation treatment to the patient via one or more of the ablation electrodes.

Electrical stimulation of specific facial and lingual nerves creates a more sustained pulsatility activity compared to stimulation of other cranial nerves. Pulsatility of arteries has intrinsic time constraints related to the time for vasodilation/constriction and time to return to baseline (TBL) after electrical stimulation which may affect the pulsatility response. Control of temporal patterning and the stimulation waveform maximizes the physiological response to cerebral pulsatility and its resulting effects on cerebral spinal fluid penetration into the brain parenchyma for a multitude of therapeutic uses including clearing misfolded proteins and/or administered pharmacological agents, diluting endogenous neurochemical concentrations within the brain, and reducing non-synaptic coupling.

Neuromodulation systems and corresponding methods for providing neuromodulation are disclosed. The neuromodulation systems can include at least one input module for inputting patient data into the neuromodulation system. The systems can further include at least one model calculation and building module for building a patient model, the patient model describing the anatomy and/or physiology and/or pathophysiology and the real and/or simulated reaction of the patient on a provided and/or simulated neuromodulation. The systems can further include at least one computation means for using the patient model (M) and calculating the impact of the provided and/or simulated neuromodulation.

The invention provides an adjustable sleep treatment device having a central nervous regulation function. The adjustable sleep treatment device comprises an arc-shape plate. The two sides of the arc-shaped plate extend to the ear-back mastoid portions and the portions are respectively provided with a stimulation electrode; the arc-shape plate is connected with at least two support plates extending to the head top portion; each support plate is provided with an acquisition electrode; the arc-shape plate is provided with USB jacks; the USB jacks are connected with conductive wires; the inner side of the arc-shape plate is provided with an installation hole; each stimulation electrode comprises an electrode column and a conductive silicon rubber sleeve; and each support is provided with a slide groove. The sleep treatment device is provided with the arc-shaped plate, and the arc-shaped plate is provided with the acquisition electrodes and the stimulation electrodes and carries out input or output through the conductive wires and the USB jacks, wherein the acquisition electrodes collect the brain wave signals so as to collect sleep state signals, and the stimulation electrodes are used for loading the stimulation current to the central nervous effectively according to the decision result of the sleep state signals collected by the former; and through central nervous regulation, sleep disorder is treated to help patients to fall asleep and improve the sleeping quality of the patients.

The present invention provides various embodiments of neuromodulation systems, and improvements thereof, capable of being implanted at a spinal treatment site and capable of being implanted at the same time and/or in combination with a spinal procedure being performed at the spinal treatment site. The present invention further includes improvements in the number and types of neuromodulation therapies that can be implanted at the spinal treatment site and improvements to the neuromodulation systems used for delivering such neuromodulation therapies.